Big Pharma Split Corp.
PRM.TO · TSX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | CA$1,849 | CA$312 | CA$3,926 | CA$5,359 |
| % Growth | 493.1% | -92.1% | -26.7% | – |
| Cost of Goods Sold | CA$316 | CA$309 | CA$420 | CA$356 |
| Gross Profit | CA$1,533 | CA$312 | CA$3,507 | CA$5,003 |
| % Margin | 82.9% | 100% | 89.3% | 93.4% |
| R&D Expenses | CA$0 | CA$0 | CA$0 | CA$0 |
| G&A Expenses | CA$541 | CA$335 | CA$358 | CA$371 |
| SG&A Expenses | CA$3,039 | CA$335 | CA$358 | CA$371 |
| Sales & Mktg Exp. | CA$0 | CA$0 | CA$0 | CA$0 |
| Other Operating Expenses | -CA$2,499 | CA$117 | CA$207 | -CA$4,827 |
| Operating Expenses | CA$541 | CA$451 | CA$565 | -CA$4,457 |
| Operating Income | CA$13 | -CA$140 | CA$3,146 | CA$4,854 |
| % Margin | 0.7% | -44.8% | 80.1% | 90.6% |
| Other Income/Exp. Net | -CA$552 | -CA$506 | -CA$756 | -CA$519 |
| Pre-Tax Income | -CA$539 | -CA$645 | CA$2,389 | CA$4,854 |
| Tax Expense | CA$0 | -CA$506 | CA$0 | CA$0 |
| Net Income | -CA$539 | -CA$140 | CA$3,146 | CA$4,854 |
| % Margin | -29.1% | -44.8% | 80.1% | 90.6% |
| EPS | -0.47 | -0.53 | 1.58 | 3.27 |
| % Growth | 11.3% | -133.5% | -51.7% | – |
| EPS Diluted | -0.47 | -0.53 | 1.58 | 3.27 |
| Weighted Avg Shares Out | 1,147 | 1,217 | 1,509 | 1,289 |
| Weighted Avg Shares Out Dil | 1,147 | 1,217 | 1,509 | 1,289 |
| Supplemental Information | – | – | – | – |
| Interest Income | CA$0 | CA$0 | CA$756 | CA$687 |
| Interest Expense | CA$560 | CA$508 | CA$760 | CA$875 |
| Depreciation & Amortization | CA$0 | CA$363 | -CA$5,762 | -CA$4,606 |
| EBITDA | CA$21 | -CA$138 | CA$3,146 | CA$4,854 |
| % Margin | 1.2% | -44.1% | 80.1% | 90.6% |